Literature DB >> 10216978

[Hepatonephritis and massive ingestion of buprenorphine].

N Houdret1, V Asnar, N Szostak-Talbodec, E Leteurtre, L Humbert, M Lecomte-Houcke, M Lhermitte, J C Paris.   

Abstract

We present a case of a severe hepatitis associated with acute renal failure and anuria consequently to the ingestion of 112 mg of buprenorphine, 48 hours before. The normalisation of hepatic and renal functions is associated with discontinuation of buprenorphine administration and hemodialysis treatment. Buprenorphine seems to be directly responsible for this hepatonephritis as indicated by the high plasmatic levels of buprenorphine (224 ng/ml) and norbuprenorphine (30 ng/ml) never described until now. Buprenorphine toxicity could be due to the inappropriate ingestion mode (oral instead of sublingual) and could be increased by previous acetaminophen intake.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216978

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  4 in total

1.  Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults.

Authors:  Michael P Bogenschutz; Patrick J Abbott; Robert Kushner; J Scott Tonigan; George E Woody
Journal:  J Addict Med       Date:  2010-12       Impact factor: 3.702

2.  Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058.

Authors:  Gregory M Lucas; Geetha Beauchamp; Apinun Aramrattana; Yiming Shao; Wei Liu; Liping Fu; J Brooks Jackson; David D Celentano; Paul Richardson; David Metzger
Journal:  Int J Drug Policy       Date:  2011-08-17

3.  Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand.

Authors:  Gregory M Lucas; Alicia Young; Deborah Donnell; Paul Richardson; Apinun Aramrattana; Yiming Shao; Yuhua Ruan; Wei Liu; Liping Fu; Jun Ma; David D Celentano; David Metzger; J Brooks Jackson; David Burns
Journal:  Drug Alcohol Depend       Date:  2014-06-19       Impact factor: 4.492

Review 4.  New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone.

Authors:  Michael Soyka
Journal:  Subst Abuse Rehabil       Date:  2015-01-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.